PT  - JOURNAL ARTICLE
AU  - T. Alex Perkins
AU  - Guido España
TI  - Optimal control of the COVID-19 pandemic with non-pharmaceutical interventions
AID  - 10.1101/2020.04.22.20076018
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.22.20076018
4099  - http://medrxiv.org/content/early/2020/04/23/2020.04.22.20076018.short
4100  - http://medrxiv.org/content/early/2020/04/23/2020.04.22.20076018.full
AB  - The COVID-19 pandemic has forced societies across the world to resort to social distancing to slow the spread of the SARS-CoV-2 virus. Due to the economic impacts of social distancing, there is growing desire to relax these measures. To characterize a range of possible strategies for control and to understand their consequences, we performed an optimal control analysis of a mathematical model of SARS-CoV-2 transmission. Given that the pandemic is already underway and controls have already been initiated, we calibrated our model to data from the US and focused our analysis on optimal controls from May 2020 through December 2021. We found that a major factor that differentiates strategies that prioritize lives saved versus reduced time under control is how quickly control is relaxed once social distancing restrictions expire in May 2020. Strategies that maintain control at a high level until summer 2020 allow for tapering of control thereafter and minimal deaths, whereas strategies that relax control in the short term lead to fewer options for control later and a higher likelihood of exceeding hospital capacity. Our results also highlight that the potential scope for controlling COVID-19 until a vaccine is available depends on epidemiological parameters about which there is still considerable uncertainty, including the basic reproduction number and the effectiveness of social distancing. In light of those uncertainties, our results do not constitute a quantitative forecast and instead provide a qualitative portrayal of possible outcomes from alternative approaches to control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors were supported by a RAPID grant from the National Science Foundation (DEB 2027718).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code and data used in our analysis is available at http://github.com/TAlexPerkins/covid19optimalcontrol. http://github.com/TAlexPerkins/covid19optimalcontrol